LONDON, Nov 4 (Reuters) - AstraZeneca Plc’s head of drug development, John Patterson, is to retire from the board of the Anglo-Swedish company next March, marking a key changeover at the top of the group.
LONDON, Nov 4 (Reuters) - AstraZeneca Plc’s head of drug development, John Patterson, is to retire from the board of the Anglo-Swedish company next March, marking a key changeover at the top of the group.
